Study S001643

A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection, for Subcutaneous Use (Once-monthly Formulation) in Adult Participants With Obesity or Overweight

ClinicalTrials.gov record

Registration

Registration: NCT07842640
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: TRIPLE
Status: RECRUITING
Enrollment: 84
Start: 2026-08-27
Primary completion: 2027-06
Lead sponsor: Ascletis Pharma (China) Co., Limited
Conditions: Chronic Weight Management
Interventions: DRUG:ASC35 Injection B, for subcutaneous use; DRUG:ASC35 Placebo Injection B, for subcutaneous use; DRUG:Tirzepatide
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Adverse events [Baseline and Day 141]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.